Register here to receive the On Demand Archive
Speaker panel from Max Neeman International:
- Ajoy Kumar, MD, Chief Executive Officer
- Donald Swankie, MBA, Vice President, USA
|
 |
Strategic ‘ex-US’ regions, and particularly the Asia-Pacific region, are becoming vital to Pharma, Biotech & Medical Device not only for cost effective, ICH GMP research services, but for post market commercialization in-country.
This program will provide overview and key lessons in leveraging India as a strategic venue for research, as well as post market approval in a growing economy whose in-country population is 1.3 Billion.
The time is ripe for major drug and device companies to start looking at India not just as a country of a billion people, but as a market that provides huge opportunities for top- and bottom-line growth.
Key Takeaway Points:
- Understanding of India’s clinical trial potential and reasons for growth
- Updated information of India’s regulatory environment
- Opportunities and risks of clinical research in India
- Process of integrating India into USA based clinical trials
*************
Access to this archive is given on the understanding that you agree to the provision of your contact information to Xtalks sponsors and partners. Only primary contact information will be shared and this information will only be shared for the purposes of providing relevant offers. This registration form is an application only. Xtalks has the right to refuse access.
If you require help with your registration or have any questions you may contact Xtalks at register@xtalks.com or phone 416-977-6555, x 371.
By completing this registration form, you agree that the information you have provided is true and accurate.
(note: fields with marked "*" are required) |